Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNASDAQ:AMRNNYSE:NUVBNASDAQ:PHAR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$7.08-6.5%$9.35$2.09▼$14.84$501.90M0.055.39 million shs2.20 million shsAMRNAmarin$0.88$0.99$0.65▼$1.49$360.82M1.981.99 million shs657,243 shsNUVBNuvation Bio$2.65-1.1%$2.55$0.95▼$4.16$577.83M1.371.20 million shs1.27 million shsPHARPharming Group$9.89+3.0%$10.89$9.27▼$16.71$663.72M0.162,598 shs2,744 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.34%+0.66%-16.63%-19.04%+37.14%AMRNAmarin+2.03%-1.41%+2.75%-23.19%-33.08%NUVBNuvation Bio-0.37%-4.81%+15.58%+62.80%+52.57%PHARPharming Group-2.47%-4.11%-14.15%-22.54%-9.58%A new way to collect income from stocks (Ad)Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune1.6167 of 5 stars3.32.00.00.03.21.70.0AMRNAmarin0.2052 of 5 stars1.93.00.00.00.00.00.6NUVBNuvation Bio3.7864 of 5 stars4.53.00.00.03.13.30.6PHARPharming Group2.5417 of 5 stars3.55.00.00.02.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.67Moderate Buy$15.00111.86% UpsideAMRNAmarin1.75Reduce$1.0823.30% UpsideNUVBNuvation Bio3.00Buy$6.60149.06% UpsidePHARPharming Group3.00Buy$37.00274.12% UpsideCurrent Analyst RatingsLatest AMRN, PHAR, NUVB, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024NUVBNuvation BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.004/1/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.003/28/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/28/2024NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/27/2024NUVBNuvation BioJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$1.40 ➝ $10.003/26/2024NUVBNuvation BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.003/14/2024PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.003/7/2024NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $5.003/1/2024NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.002/13/2024ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.001/24/2024ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$13.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,167.21N/AN/A$2.75 per share2.57AMRNAmarin$306.91M1.18N/AN/A$1.35 per share0.65NUVBNuvation BioN/AN/AN/AN/A$2.76 per shareN/APHARPharming Group$245.32M2.71$0.10 per share101.77$3.26 per share3.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)AMRNAmarin-$59.11M-$0.14N/AN/AN/A-19.26%-10.47%-6.97%5/1/2024 (Confirmed)NUVBNuvation Bio-$75.80M-$0.34N/AN/AN/AN/A-12.21%-11.89%5/2/2024 (Estimated)PHARPharming Group-$10.55M-$0.14N/AN/AN/A-4.13%-4.53%-2.14%5/8/2024 (Confirmed)Latest AMRN, PHAR, NUVB, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/APHARPharming Group$0.0050N/A-$0.0050N/AN/AN/A5/1/2024N/AAMRNAmarin-$0.0350N/A+$0.0350N/AN/AN/A 3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 million3/14/2024Q4 2023PHARPharming Group$0.05-$0.03-$0.08-$0.02$71.83 million$81.20 million2/29/2024Q4 2023AMRNAmarin-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 million2/29/2024Q4 2023NUVBNuvation Bio-$0.10-$0.06+$0.04-$0.06N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A17.2617.26AMRNAmarinN/A2.801.80NUVBNuvation BioN/A44.1144.11PHARPharming Group0.624.063.33OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AMRNAmarin22.25%NUVBNuvation Bio61.67%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%AMRNAmarin1.96%NUVBNuvation Bio36.09%PHARPharming Group2.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.89 million67.99 millionOptionableAMRNAmarin275410.67 million402.62 millionOptionableNUVBNuvation Bio51218.05 million139.35 millionOptionablePHARPharming Group33267.11 million65.72 millionNot OptionableAMRN, PHAR, NUVB, and ALT HeadlinesSourceHeadlinePharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awardsfinance.yahoo.com - April 24 at 2:17 AMPharming Group to report first quarter 2024 financial results on May 8finance.yahoo.com - April 24 at 2:17 AMPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.00marketbeat.com - April 22 at 1:31 PMPharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?zacks.com - April 22 at 6:31 AMPharming Group (NASDAQ:PHAR) Sees Large Volume Increaseamericanbankingnews.com - April 21 at 4:44 AMPharming Group (NASDAQ:PHAR) Hits New 1-Year Low at $9.35americanbankingnews.com - April 20 at 4:40 AMPharming Group N.V.: Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025finanznachrichten.de - April 19 at 4:05 PMPharming Group (NASDAQ:PHAR) Sees Strong Trading Volumemarketbeat.com - April 19 at 1:37 PMPharming Group N.V.: Pharming Group announces the placement of €100 million convertible bonds due 2029finanznachrichten.de - April 18 at 6:18 PMPharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025finance.yahoo.com - April 18 at 8:17 AMPharming Group (NASDAQ:PHAR) Stock Price Down 6.8%marketbeat.com - April 15 at 1:55 PMPharming Group (NASDAQ:PHAR) Shares Gap Down to $11.30americanbankingnews.com - April 14 at 2:32 AMPharming Group (NASDAQ:PHAR) Shares Down 5% marketbeat.com - April 9 at 3:19 PMEnrollment completed for trial of drug to treat children with rare primary immunodeficiencyoutsourcing-pharma.com - April 8 at 8:50 AMPharming announces completion of enrollment in pediatric clinical trial of leniolisibfinance.yahoo.com - April 8 at 1:34 AMPharming Group (NASDAQ:PHAR) Shares Gap Down to $10.96marketbeat.com - April 4 at 6:21 PMPharming Group announces the filing of its 2023 Annual Report and Form 20-Ffinance.yahoo.com - April 4 at 1:14 AMUber to pay $178 million in Australia taxi class action settlementmsn.com - March 18 at 3:45 AMPharming reports Q4 resultsmsn.com - March 15 at 7:46 PMPharming Group N.V. 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - March 14 at 9:06 AMPharming Group N.V.: Pharming Group to report fourth quarter and full year 2023 financial results on March 14finanznachrichten.de - February 29 at 6:26 AMPharming Group N.V. (PHGN.F)finance.yahoo.com - February 20 at 3:10 PMPharming Group N.V.: Pharming Group to participate in February investor conferencesfinanznachrichten.de - February 8 at 3:55 AMPharming Group to participate in February investor conferencesfinance.yahoo.com - February 8 at 3:55 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentAkebia Therapeutics Surges on FDA Approval for Anemia TreatmentApril 3, 2024 9:10 AMView Akebia Therapeutics Surges on FDA Approval for Anemia TreatmentCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Biotech Sector Nears Breakout: Will it Outperform in Q2?April 3, 2024 6:10 AMView Biotech Sector Nears Breakout: Will it Outperform in Q2?All Headlines Company DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.AmarinNASDAQ:AMRNAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Nuvation BioNYSE:NUVBNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Pharming GroupNASDAQ:PHARPharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.